Clinical Trials Logo
  1. Home
  2. Stomach Neoplasms
  3. NCT02136836
  4. Details
NCT02136836 Clinical Trial

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Stomach Neoplasms Clinical Trial

— HER2  

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02136836
Other study ID # GSCH-STO13-01
Secondary ID Roche
Status Active, not recruiting
Phase N/A
First received May 8, 2014
Last updated May 12, 2014
Start date May 2014

Study information
Verified date April 2014
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority Korea: Institutional Review Board
Study type Observational

Clinical Trial Summary

The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 860
Est. completion date
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

1. Histologically confirmed gastric adenocarcinoma

2. Patients were diagnosed during 2006-2013

3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.

Exclusion Criteria:

- Patients with second primary cancer within 5 years

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Gangnam Severance Hospital Seoul

Sponsors (1)
Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Other The practice pattern of Herceptin use in stage IV gastric cancer 3 years No
Primary The proportion of HER2 overexpression in gastric cancer patients 8 years No
Secondary Gastric cancer specific survival according to HER2 expression in each stage 5 years No
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04351867 - A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer Phase 3
Recruiting NCT02887612 - ctDNA for Prediction of Relapse in Gastric Cancer
Active, not recruiting NCT02930291 - The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy
Completed NCT02649348 - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome N/A
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Active, not recruiting NCT01609309 - Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01) Phase 3
Completed NCT00375999 - Docetaxel and Epirubicin in Advanced Gastric Cancer Phase 2
Completed NCT00382720 - Docetaxel and Oxaliplatin in Gastric Cancer Phase 2
Completed NCT00980382 - A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma Phase 1/Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT05033392 - PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer Phase 2
Completed NCT04539769 - Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes Phase 2
Active, not recruiting NCT02930278 - The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy
Active, not recruiting NCT02845986 - Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer Phase 2
Completed NCT02902575 - The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy N/A
Recruiting NCT04222114 - Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis Phase 3
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4